Alnylam Pharmaceuticals Inc (ALNY)vsChemomab Therapeutics Ltd DRC (CMMB)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CMMB
Chemomab Therapeutics Ltd DRC
$1.57
-6.55%
HEALTHCARE · Cap: $10.96M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
CMMB
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for CMMB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CMMB
The strongest argument for CMMB centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CMMB
The primary concerns for CMMB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CMMB is a value play — different risk/reward profiles.
CMMB carries more volatility with a beta of 0.54 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 26/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Chemomab Therapeutics Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?